Adilet Nazarbayev

Adilet Nazarbayev, CIS Cluster Lead of Johnson &Johnson Kazakhstan, was elected to the Board of Directors of the American Chamber of Commerce (AmCham) in Kazakhstan for a two-year term beginning in February 2024.

“Joining the AmCham Board of Directors is a great honour for me. I will make every effort to ensure that my management experience and expertise in healthcare will be a useful contribution. Working together within the organisation will further strengthen the business community, thecountry's economy, and the well-being of the people of Kazakhstan”.

Adilet Nazarbayev joined Janssen, the pharmaceuticalproducts division of Johnson & Johnson in 2005, beginning his career as a sales representative. In 2014, he was appointed Head of Janssen in Kazakhstan and in 2019 he was promoted to Head of Business Development for CIS and Ukraine, responsible for Janssen’s strategic development in the region. InJanuary 2021 he was appointed Janssen CIS Country Director, and in early 2024 he became Head of the independent local legal entity Johnson & JohnsonKazakhstan.

In 2019, AdiletNazarbayev received the “Excellence in Healthcare” commendation from the Minister of Health of Kazakhstan for his contribution to public health and participation in improving the country's healthcare system. He is Chairman of the AmCham Intellectual Property Rights (Pharmaceuticals) Working Group,which meets regularly with the Health Minister to discuss recommendations forthe country’s healthcare system.